Merck gets a PDUFA date for its chronic cough contender; Morphic shares skyrocket on the heels of PhI data rollout in IBD
Merck should know before the end of this year whether or not the FDA will approve its drug gefapixant for chronic cough. The regulator has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
